Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETAreceptor antagonist

2000 ◽  
Vol 13 (2) ◽  
pp. 87-97 ◽  
Author(s):  
Ronald G. Tilton ◽  
Christy L. Munsch ◽  
Sidney J. Sherwood ◽  
Shi-Juan Chen ◽  
Yiu-Fai Chen ◽  
...  
Keyword(s):  
Cardiac Hypertrophy ◽  
Orally Active ◽  
Pulmonary Vascular Hypertension

scholarly journals The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy

2015 ◽  
Vol 172 (10) ◽  
pp. 2618-2633 ◽  
Author(s):  
K S Oh ◽  
J H Lee ◽  
K Y Yi ◽  
C J Lim ◽  
S Lee ◽  
...  
Keyword(s):  
Cardiac Hypertrophy ◽  
Receptor Antagonist ◽  
Orally Active

421 The NFATc2 isoform plays a major role in calcineurin-induced cardiac hypertrophy

2006 ◽  
Vol 5 (1) ◽  
pp. 98-98
Author(s):  
M BOURAJJAJ ◽  
A ARMAND ◽  
B WEIJTS ◽  
L DEWINDT
Keyword(s):  
Cardiac Hypertrophy

Sex differences in cardiac hypertrophy are linked to adipose tissue lipolysis

2011 ◽  
Vol 6 (S 01) ◽  
Author(s):  
A Foryst-Ludwig ◽  
M Kreissl ◽  
C Sprang ◽  
B Thalke ◽  
C Böhm ◽  
...  
Keyword(s):  
Sex Differences ◽  
Adipose Tissue ◽  
Cardiac Hypertrophy ◽  
Adipose Tissue Lipolysis
Sign in / Sign up

Export Citation Format

Share Document